Heptares Therapeutics Ltd.

When Chris Cargill became president and CEO of Sosei Heptares in March 2022, high on his initial to-do list were a number of items around the transition of the Japan-UK company to the next stage of

Karuna Therapeutics, Inc. hopes to raise at least $600m on the back of better-than-expected Phase III efficacy data for its novel therapy for schizophrenia that have set the product on a path to a US

GlaxoSmithKline plc has continued its flurry of R&D deal-making by becoming the latest major drug maker to partner with Sosei Heptares and inked a deal targeting immune disorders of the digestive s

Italian gene therapy company Genespire has pulled off quite a coup with the news that Jörn Aldag, former head of uniQure N.V. and current CEO of HOOKIPA Pharma Inc. , is to be chairman of the boa